Cadrenal Therapeutics (CVKD)

• Market cap: $21.1M
• 1 day: -8.29%
• 5 days: 12.49%
• 1 month: -20.16%
• 3 months: -23.17%
• 6 months: -30.32%
• Year to date: -34.32%
• 1 year: -23.86%
• 5 years: -83.53%
• 10 years: -83.53%
• Sector: Healthcare
• Industry: Biotechnology

About: Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Employees: 4